Neuromyelitis Optica Spectrum Disorder: Modern Approaches to Diagnosis and Treatment
December 31, 2021
December 31, 2022
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education.
This activity is supported by an independent grant from Alexion Pharmaceuticals.
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)™
- Nurses — maximum of 0.75 contact hours of nursing continuing professional development (NCPD)
- Pharmacists - maximum of 0.75 contact hours of continuing pharmacy education credit
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of neurologists, nursing professionals, PAs, pharmacists, and other healthcare professionals involved in the management of patients with neuromyelitis optica spectrum disorder (NMOSD).
The enduring activity is designed to provide evidence-based education on the diagnosis of patients with NMOSD, evidence on novel treatments, and considerations in personalizing therapy.
Upon completion of this activity, participants should be better able to:
- Define signs and symptoms of NMOSD
- Review diagnostic testing methods for NMOSD
- Utilize consensus diagnostic criteria to support the diagnosis of NMOSD
- Review mechanisms of action of novel targeted therapies for NMOSD
- Apply evidence on novel therapies to the treatment of patients with NMOSD
Dean Wingerchuk, MD, MSc, FRCP(C)
Professor and Chair
Department of Neurology
In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation
The CMSC designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit Designation
The CMSC designates this activity for a maximum of 0.75 contact hours of nursing continuing professional development (NCPD) (0.75 in the area of pharmacology).
Pharmacists Credit Designation
This knowledge-based activity, UAN JA4008165-9999-21-043-H01-P, qualifies for 0.75 contact hours (.075 CEUs) of continuing pharmacy education credit.
Disclosures of Conflicts of Interest
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC requires that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies (formerly commercial interests). CMSC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC seeks to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC is committed to providing learners with high-quality CE activities that promote improvements in healthcare and not those of a commercial interest.
- Dean Wingerchuk, MD, MSc, FRCP(C)
- Consulting fees: Genentech, Horizon, Roche, UCB Pharma, Viela Bio
Activity Staff Disclosures
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have disclosed no relevant financial relationships.
All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at The Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, CE committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.
Instructions for Participation and Credit
This activity is an online enduring material. There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CME information, completing the pre-test, viewing the video, studying the educational activity, and completing the post-test and the evaluation form. Upon completion of the evaluation, your certificate will be made available immediately. Click on "View Certificate" and print the certificate for your records.
The estimated time to complete the activity is 45 minutes.
This activity was originally released on December 31, 2021, and is eligible for credit through December 31, 2022.
Course Viewing Requirements
This site is best viewed with an HTML5 compatible browser. You can visit the independent
(third-party) site www.whatismybrowser.com to determine if you have the latest version of your browser.
Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and RealPlayer.
Our Policy on Privacy
The Consortium of Multiple Sclerosis Centers and Catamount Medical Education, LLC, respect your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the post-test and evaluation results for CE credit. This information is provided to activity collaborators for the purposes of CE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information.
Catamount Medical Education, LLC, safeguards against the loss, misuse, or alteration of information that we have collected in this activity.
Disclosure of Unlabeled Use
CMSC and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For questions about this activity, please contact Catamount Medical Education at firstname.lastname@example.org.